4.06 USD
0 (0%)
4.08 USD
+0.02 (+0.49%)
ChartMill assigns a Buy % Consensus number of 78% to THRX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 5.36. This target is 31.9% above the current price.
THRX was analyzed by 9 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about THRX.
In the previous month the buy percentage consensus was at a similar level.
THRX was analyzed by 9 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-07-14 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2023-07-14 | Needham | Downgrade | Buy -> Hold |
| 2023-07-14 | Wedbush | Maintains | Outperform -> Outperform |
| 2023-07-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-05-26 | Needham | Reiterate | Buy -> Buy |
| 2023-05-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-17 | Needham | Reiterate | Buy -> Buy |
| 2023-05-12 | Needham | Reiterate | Buy -> Buy |
| 2023-05-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-03-16 | Stifel | Initiate | Buy |
| 2023-03-10 | Needham | Reiterate | Buy |
| 2023-03-10 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-12-14 | Needham | Initiate | Buy |
| 2022-06-30 | HC Wainwright & Co. | Initiate | Buy |
| 2021-11-01 | Cantor Fitzgerald | Initiate | Overweight |
| 2021-11-01 | SVB Leerink | Initiate | Outperform |
| 2021-11-01 | Wedbush | Initiate | Outperform |
| 2021-11-01 | Jefferies | Initiate | Buy |
THESEUS PHARMACEUTICALS INC / THRX FAQ
What is the average price target for THESEUS PHARMACEUTICALS INC (THRX) stock?
9 analysts have analysed THRX and the average price target is 5.36 USD. This implies a price increase of 31.9% is expected in the next year compared to the current price of 4.06.
How do analysts rate THESEUS PHARMACEUTICALS INC (THRX)?
The consensus rating for THESEUS PHARMACEUTICALS INC (THRX) is 77.7778 / 100 . This indicates that analysts generally have a positive outlook on the stock.